iLIVER最新文献

{"title":"Reply to Dr. Sun et al.: Female DILI patients need more clinical attention","authors":"Yu-Ting Xiong, Chun-Yan Wang, Dong Ji","doi":"10.1016/j.iliver.2024.100126","DOIUrl":"10.1016/j.iliver.2024.100126","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 4","pages":"Article 100126"},"PeriodicalIF":0.0,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142706993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased attention to women with drug-induced liver injury: Risk factors and early intervention","authors":"Xiaoru Sun ,&nbsp;Xinrong Zhang ,&nbsp;Muyun Liu","doi":"10.1016/j.iliver.2024.100125","DOIUrl":"10.1016/j.iliver.2024.100125","url":null,"abstract":"<div><div>A recent study by Xiong Yu-Ting and colleagues has unveiled the clinical characteristics and risk factors of acute drug-induced liver injury (DILI). Upon reading the article, we found that there are some differences between female and male patients with DILI in terms of clinical and pathological features, especially in the number of patients, the degree of liver inflammation, and the risk of autoimmune liver disease. Therefore, it is necessary to pay attention to female patients with DILI and their outcomes, and to intervene appropriately in advance. This article analyzes the reasons for the differences between female and male patients with DILI and makes recommendations for patient prognosis.</div></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 4","pages":"Article 100125"},"PeriodicalIF":0.0,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142651488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Arginine methylation modification in the malignant progression of benign and malignant liver diseases","authors":"Jie-Zuo Huang ,&nbsp;Bei-Ning Qiao ,&nbsp;Dang-Chi Li ,&nbsp;Qiu-Rong Wei ,&nbsp;Zi-Jian Zhang","doi":"10.1016/j.iliver.2024.100124","DOIUrl":"10.1016/j.iliver.2024.100124","url":null,"abstract":"<div><div>The role of protein arginine methyltransferases (PRMTs) in benign and malignant liver diseases has garnered considerable attention. PRMTs play a key function in regulating protein methylation modification in diseases such as alcoholic fatty liver disease, metabolic dysfunction–associated steatotic liver disease, viral hepatitis, and hepatocellular carcinoma. This review explores the mechanisms of action of PRMTs in these diseases, with a focus on their effects on cell signaling, transcriptional regulation, cell proliferation, and metabolism. We also discuss potential therapeutic strategies targeting PRMTs and propose future research directions. This review helps deepen the understanding of the important role of arginine methylation modification in the malignant progression of liver diseases and provides guidance for future clinical treatment and drug development.</div></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 4","pages":"Article 100124"},"PeriodicalIF":0.0,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142528996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gd-EOB-DTPA-enhanced MRI proves advantageous in selecting surgical candidates for patients with early-stage hepatocellular carcinoma: An analysis in terms of oncological outcomes","authors":"Zhiwei Ye ,&nbsp;Jing Zhao ,&nbsp;Dandan Hu ,&nbsp;Zhoutian Yang ,&nbsp;Jinbin Chen ,&nbsp;Li Xu ,&nbsp;Zhongguo Zhou ,&nbsp;Minshan Chen ,&nbsp;Yaojun Zhang","doi":"10.1016/j.iliver.2024.100117","DOIUrl":"10.1016/j.iliver.2024.100117","url":null,"abstract":"<div><h3>Background and aims</h3><div>To determine the value of preoperative Gd-EOB-DTPA-enhanced magnetic resonance imaging (MRI) in comparison with extracellular contrast agent MRI and CT in the selection of surgical candidates among patients with hepatocellular carcinoma (HCC), particularly in terms of oncological outcomes after hepatectomy.</div></div><div><h3>Methods</h3><div>This retrospective study included 542 consecutive patients who underwent radical hepatectomy for HCC. One group underwent preoperative Gd-EOB-DTPA-enhanced MRI, one group underwent contrast-enhanced CT, and one group underwent extracellular contrast agent MRI. We compared oncologic outcomes including recurrence free survival and overall survival between the three groups. Subgroup analyses were also performed to provide more specific candidates or beneficiaries for preoperative EOB-MRI.</div></div><div><h3>Results</h3><div>A total of 244 patients had tumor recurrence, with 55 in the EOB-MRI group, 106 in the Routine-MRI group, and 83 in the CT group (<em>p</em> = 0.010). The numbers with early recurrence (&lt;2 years) in each group were 40 (27.03%), 78 (35.78%), and 62 (35.22%), respectively (<em>p</em> = 0.018). The 1, 2, and 3-year recurrence-free survival (RFS) percentages were 82.4%, 73.0%, and 68.2% in the EOB-MRI group, 70.2%, 64.3%, and 56.9% in the Routine-MRI group, and 76.8%, 64.83%, and 58.9% in the CT group (<em>p</em> = 0.010). The 1, 2, and 3-year overall survival percentages were 89.19%, 83.11%, and 80.41% in the EOB-MRI group, 79.82%, 73.86%, and 67.44% in the Routine-MRI group, and 86.55%, 76.14%, and 69.32% in the CT group (<em>p</em> = 0.016). Subgroup analysis showed significant differences in RFS in patients with solitary tumor &lt;3 cm.</div></div><div><h3>Conclusion</h3><div>Preoperative EOB-MRI is superior to contrast-enhanced CT or extracellular contrast agent MRI for selecting surgical candidates at low risk of recurrence following hepatic resection for HCC.</div></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 4","pages":"Article 100117"},"PeriodicalIF":0.0,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142434033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiomic predictors for regression of cirrhosis: Clinical implications and future directions","authors":"Binghua Li,&nbsp;Decai Yu","doi":"10.1016/j.iliver.2024.100116","DOIUrl":"10.1016/j.iliver.2024.100116","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 4","pages":"Article 100116"},"PeriodicalIF":0.0,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142426498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Network pharmacology and single-cell transcriptomic analysis with molecular docking to elucidate the potential compounds and targets of Polygonum cuspidatum Sieb.et Zucc. for hepatocellular carcinoma","authors":"Wenze Wu ,&nbsp;Yuzhu Shi ,&nbsp;Yongzi Wu ,&nbsp;Rui Zhang ,&nbsp;Xinyan Wu ,&nbsp;Weidi Zhao ,&nbsp;Zhiyuan Chen ,&nbsp;Gang Ye","doi":"10.1016/j.iliver.2024.100115","DOIUrl":"10.1016/j.iliver.2024.100115","url":null,"abstract":"<div><h3>Background and aims</h3><p><em>Polygonum cuspidatum</em> Sieb.et Zucc. (<em>P. cuspidatum</em>) and its active components have been clinically proven to have anti-hepatocellular carcinoma effects. However, the potential targets of <em>P. cuspidatum</em> for these effects have not yet been revealed.</p></div><div><h3>Methods</h3><p>We used network pharmacology and single-cell transcriptomic analysis with molecular docking to elucidate the active components and targets of <em>P. cuspidatum</em> for hepatocellular carcinoma.</p></div><div><h3>Results</h3><p>CDK1, ESR1, HSP90A11, and MAPK1 were shown to be the key targets of <em>P. cuspidatum</em> for hepatocellular carcinoma. <em>P. cuspidatum</em> was found to be likely correlated with the improved abnormal expression of CDK1 and ESR1 and the poor prognosis of HSP90AA1 and MAPK1. CDK1 was identified as the most potential anti-hepatocellular carcinoma target of <em>P. cuspidatum</em>. Among the active components of <em>P. cuspidatum</em>, physcion diglucoside was found to have the most potential to treat hepatocellular carcinoma by targeting CDK1.</p></div><div><h3>Conclusion</h3><p>Our study provides novel insights into the anti-hepatocellular carcinoma pharmacological effects of <em>P. cuspidatum</em>, which could serve as a scientific basis for its development as a medicinal resource and the targeting of CDK1 for hepatocellular carcinoma treatment.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 3","pages":"Article 100115"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000409/pdfft?md5=11fd39f142c9e35b0e9dd563005a3e5a&pid=1-s2.0-S2772947824000409-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142172692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transarterial chemoembolization plus radiofrequency ablation: One of the effective interventions for hepatocellular carcinoma","authors":"Yong Xie,&nbsp;Jian Wang,&nbsp;Yinghua Zou","doi":"10.1016/j.iliver.2024.100114","DOIUrl":"10.1016/j.iliver.2024.100114","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 3","pages":"Article 100114"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000392/pdfft?md5=872f44ce832e9d7fb0cf35da0ff3d221&pid=1-s2.0-S2772947824000392-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142172767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting hepatocellular carcinoma growth and metabolism: A synergistic approach with para-toluenesulfonamide and radiofrequency ablation","authors":"Na Liu ,&nbsp;Jianzeng Zhang ,&nbsp;Jiaojiao Wu ,&nbsp;Fan Feng ,&nbsp;Yantao Chai ,&nbsp;Yongwu Li ,&nbsp;Bo Liu","doi":"10.1016/j.iliver.2024.100111","DOIUrl":"10.1016/j.iliver.2024.100111","url":null,"abstract":"<div><h3>Background and aims</h3><p>Hepatocellular carcinoma (HCC) is one of the most prevalent and lethal forms of cancer, posing challenges to standard treatment methods. Radiofrequency ablation (RFA) has emerged as a valuable technique for the local control of advanced HCC, especially in cases unsuitable for surgical resection. Para-toluenesulfonamide (PTS) has demonstrated antitumor properties in various cancers, yet its efficacy against HCC remains underexplored. The present study aims to investigate the therapeutic potential of PTS in HCC and examine potential synergistic effects with RFA.</p></div><div><h3>Methods</h3><p>PTS was injected directly into subcutaneous tumor tissues and its effects on cell survival, gene expression, and metabolic activity in HCC cells were evaluated. The effect of PTS and RFA in combination on HCC growth was examined using a nude mouse model of subcutaneous HCC. Data were visualized using heat maps.</p></div><div><h3>Results</h3><p>PTS inhibited the survival of HCC cells in a dose-dependent manner, modulating the expression of key genes related to cell survival, apoptosis, epithelial–mesenchymal transition, and proliferation. The combination of PTS and RFA markedly enhanced the inhibition of HCC tumor growth and induced alterations in cellular metabolism.</p></div><div><h3>Conclusion</h3><p>Combining PTS and RFA may be a promising approach to improve the efficacy of HCC treatment.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 3","pages":"Article 100111"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000367/pdfft?md5=b0e8499504bb732be1b53d5b3ef270e3&pid=1-s2.0-S2772947824000367-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142098567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unraveling the epidemiology of metabolic dysfunction-associated liver cancer: Insights from mixed etiologies, regional variations, and gender disparities","authors":"Gong Feng ,&nbsp;Ya-Fei Fan ,&nbsp;Ru-Xin Li ,&nbsp;Giovanni Targher ,&nbsp;Christopher D. Byrne ,&nbsp;Ming-Hua Zheng","doi":"10.1016/j.iliver.2024.100113","DOIUrl":"10.1016/j.iliver.2024.100113","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 3","pages":"Article 100113"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000380/pdfft?md5=900c268f6fb3052db25147560b9aa2ec&pid=1-s2.0-S2772947824000380-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142098566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic treatment in unresectable hepatocellular carcinoma: The most concerns","authors":"Jian-Hong Zhong,&nbsp;Kang Chen,&nbsp;Ze Su,&nbsp;Shao-Ping Liu,&nbsp;Fan-Jian Zeng,&nbsp;Lin Ye,&nbsp;the GUIDANCE investigators","doi":"10.1016/j.iliver.2024.100112","DOIUrl":"10.1016/j.iliver.2024.100112","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 3","pages":"Article 100112"},"PeriodicalIF":0.0,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000379/pdfft?md5=520af061d7f9f40ec565cf72ac9acec5&pid=1-s2.0-S2772947824000379-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142076358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}